|
|
| | Resolvin D4 Basic information |
| Product Name: | Resolvin D4 | | Synonyms: | Resolvin D4;6,8,10,13,15,19-Docosahexaenoic acid, 4,5,17-trihydroxy-, (4S,5R,6E,8E,10Z,13Z,15E,17S,19Z)- | | CAS: | 1025684-60-9 | | MF: | C22H32O5 | | MW: | 376.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1025684-60-9.mol |  |
| | Resolvin D4 Chemical Properties |
| Boiling point | 609.2±55.0 °C(Predicted) | | density | 1.101±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 0.5 mg/ml | | pka | 4.50±0.10(Predicted) |
| | Resolvin D4 Usage And Synthesis |
| Uses | Resolvin D4 is a critical specialized proresolving mediator that limits NETosis in the formation of the clot, as well as regulating the rate of clot resolution. | | Definition | ChEBI: Resolvin D4 is a member of the class of resolvins that is (6E,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 5 and 17 (the 4S,5R,17S-stereoisomer). It has a role as an anti-inflammatory agent and a human xenobiotic metabolite. It is a resolvin, a secondary allylic alcohol, a triol and a hydroxy polyunsaturated fatty acid. | | in vivo | Resolvin D4 (RvD4, 10ng/mouse) decreases percent of PMN, giving ~31% reduction at 4 hours[1].
Resolvin D4 (RvD4, 10ng/mouse) modulates the severity of thrombo-inflammatory disease in vivo and improves thrombus resolution[2].
| Animal Model: | 6-8-week-old male FVB mice (a self-limited bacterial inoculation (105 c.f.u) into the dorsal pouch)[1].
| | Dosage: | 200ng/mouse (saline containing 0.01% EtOH). | | Administration: | I.P.. | | Result: | Gave lower PMN levels in the cavity in mice treated with RvD4.
Significantly lowered bacterial counts when compared to vehicle control.
Stopped leukocyte influx to the site of infection in the dorsal pouch cavity as well as the inflammation-initiating eicosanoids by reducing levels of PGD2 and LTB4.
|
| Animal Model: | Thrombus-bearing mice[2].
| | Dosage: | 3 μg. | | Administration: | IV via tail vein injection on day 1 and day 4 after IVC stenosis. | | Result: | Accelerated venous thrombus resolution in mice. |
|
| | Resolvin D4 Preparation Products And Raw materials |
|